Last reviewed · How we verify

NCT04065516: ARAT

ARAT for Reflux Disease After Peroral Endoscopic Myotomy in Patients With Achalasia

ENROLLING BY INVITATION NA Last updated 25 April 2025
What this trial tests

NA trial testing ARAT technique in Achalasia in 44 participants. Enrolling by invitation.

Timeline
3 July 2019
Primary endpoint
1 July 2026
1 December 2026

Quick facts

Lead sponsorCoordinación de Investigación en Salud, Mexico
PhaseNA
StatusENROLLING BY INVITATION
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment44
Start date3 July 2019
Primary completion1 July 2026
Estimated completion1 December 2026
Sites1 location across Mexico

Drugs / interventions tested

Conditions studied

Sponsor

Coordinación de Investigación en Salud, Mexico — full company profile →

Who can join

18 and older, any sex, with Achalasia or Gastroesophageal Reflux. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The peroral endoscopic myotomy for the treatment of achalasia is associated with a higher incidence of gastroesophageal reflux disease compared with Heller's myotomy. Remodeling of the esophagogastric junction with hybrid argon plasma could decrease the passage of gastric or gastroduodenal content into the esophagus.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Achalasia

Currently open trials in the same condition.

Other Coordinación de Investigación en Salud, Mexico trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04065516.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing